Biotricity INC.: insider trades · United States · SEC (Form 4)

About Biotricity INC.

Biotricity Inc. (ticker BTCY) is a U.S.-listed medical technology company traded on the NASDAQ market in the United States. Headquartered in Redwood City, California, the company was incorporated in 2012 and has evolved into a remote biometrics and digital diagnostics platform focused on chronic-condition monitoring, especially in cardiac care. Its business model is built around Technology-as-a-Service (TaaS), combining medical devices, software, recurring service fees, and data analytics rather than relying solely on one-time hardware sales. Biotricity’s core business centers on cardiac monitoring and remote diagnostic solutions. The company develops and commercializes ECG monitoring devices and related digital health applications that enable physicians to monitor patients remotely and support diagnosis and post-diagnostic care. Its product portfolio has included Bioflux, Biotres, Bioheart, and more recently the cellular Biocore Pro, which management has described as a flagship technology. This product mix reflects a strategy aimed at creating a connected care ecosystem for clinicians and patients, with recurring revenue increasingly tied to software-like Technology Fees and service subscriptions. From a competitive standpoint, Biotricity operates in the attractive but crowded remote patient monitoring and cardiac diagnostics market. The company differentiates itself through a focused specialty in cardiovascular disease, a platform-oriented offering, and its emphasis on workflow automation, AI-enabled enhancements, and operational efficiency. Its solutions are designed to help cardiologists, electrophysiologists, and other healthcare professionals improve patient compliance, detect issues earlier, and manage chronic conditions more efficiently. In that sense, Biotricity is positioned as a niche digital health player rather than a broad-based medtech conglomerate. Geographically, the company is primarily U.S.-based, with its principal operating presence in California. Its commercial footprint is concentrated in the United States, though the addressable market it targets is broader and tied to the global trend toward connected, data-driven healthcare. Recent corporate updates have emphasized revenue growth, margin expansion, improving EBITDA, and operational progress, suggesting that the company is moving toward a more scalable business profile. Recent developments have been notable. In 2025 and 2026, Biotricity reported stronger quarterly performance, including higher revenue, improved margins, and expanding EBITDA, while continuing to communicate a more disciplined cost structure. The company also announced investor presentation activity in May 2026, signaling continued capital markets engagement. For investors, BTCY remains a small-cap healthcare technology name with a differentiated remote cardiac monitoring franchise, but it still carries the typical risks of early-stage commercialization, competitive intensity, and execution dependence.